Advancing Access to LEN for PrEP in Kenya, Malawi and Uganda: Communications Toolkit

These communication materials were created during the Advancing Access to LEN for PrEP projects in Kenya, Malawi and Uganda. Partners worked with government and communities to develop tailored materials to raise awareness of LEN for PrEP, situating it among other available prevention options as a way of facilitating informed choice. Across the three countries, 36 demand-generation materials were developed with community input. If you have any specific needs or requests in using these resources, please contact [email protected].

Advancing Access to LEN for PrEP

Lessons from early LEN introduction in Kenya, Malawi and Uganda

Key achievements and recommendations for future prevention rollouts.

Learn more about the project

Kenya

Malawi

Uganda

Going Faster with LEN Generics

The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation. The rapid granting of voluntary licensing by Gilead also contributes to this shorter timeline. For the latest on LEN, visit here.

Avac Event

Understanding Anal Pleasure and Health: There’s Always More to Know

The public health response to the HIV epidemic can narrow our attention to the potential harms of anal sex. Forty-five years into the epidemic, people are still seeking accurate, reliable information about anal play that goes beyond HIV and STI prevention. They want to understand how to maximize pleasure and reduce other potential harms. Too often, harmful myths fill the gaps, leaving people to learn through trial and error and encounter preventable harms along the way.

This 90-minute webinar is designed for HIV and STI clinicians, behavioral health workers, social workers, case managers, advocates, peers, and others who provide or refer people to HIV treatment, PrEP, testing, and support services. We will share findings from PEACHES 1.0, a study focused on building comfort and confidence in discussing anal pleasure, health, and harm reduction with people of all backgrounds who engage in anal play. Participants will learn why addressing anal pleasure and health is essential in HIV service settings and explore practical ways to respond to frequently asked questions, drawing on an updated website for clients and service providers.

Speaker:

  • Dr. Bryan Kutner, Albert Einstein College of Medicine

Avac Event

4th African Workshop on Women & HIV 2027

The fourth edition of the African Workshop on Women & HIV will take place on 25 – 26 February 2027 in Lusaka, Zambia. It is an opportunity for both local and international healthcare providers, researchers, government, industry, and community representatives to discuss and further increase their knowledge on the issues related to HIV and women living in Africa. This year’s program will explore how language shapes stigma, the role of communities and the engagement of men in empowering women, and the intersection of digital spaces and adolescent mental health.

The format of the workshop enables attendees to learn from renowned HIV experts, participate in interactive skills-building sessions, and discuss challenges, gaps, and opportunities for further learning and research. It also provides a forum for early-career investigators to present their research and to personally meet with experts they view as mentors and inspiration for their work.

Avac Event

Lower-Cost HIV Tests: Advocacy for better diagnostic deals

Opportunities to expand access to high quality testing services while freeing up funding for HIV prevention and treatment.

Engagement with diagnostic procurers for the purchase of lower cost diagnostic products is critical given reductions in funding for health programs. International Planned Parenthood Federation’s recent survey on HIV stock-outs in 40 countries showed HIV rapid tests to be the most critically affected product. Global Fund is open to support countries’ adoption of low-cost, WHO pre-qualified HIV tests—both rapid diagnostic tests (RDTs) and HIV self-testing (HIVST). But advocates have a role to play, ensuring both national-level and Global Fund purchase of lower-cost HIV testing products to better sustain testing services and free up funding. In this webinar, AVAC, CHAI, and the WHO unpacked some of the basics on HIV testing, pricing and procurement, and began a discussion about potential advocacy for change.

Objectives:

  • Equip advocates with knowledge of lower-cost HIV RDTs and HIVST opportunities for cost-savings and expanded accesses to HIV products and services, and
  • Outline country-level decision points, cost-saving opportunities, and advocacy actions. for the uptake of lower-cost diagnostics.

Agenda:

Session / Slide PresentationsFacilitator
Framing the state of HIV testing services and future needsWHO, Celine Lastrucci
Rapid Diagnostic Tests and HIV Self-Testing —products and costsCHAI, Megan Ginivan
Advocacy for product adoption—national level Afrocab, Bahati Haule
Advocacy for product adoption—Global FundGlobal Fund, Marian Honu
Discussion and next stepsAVAC

Press Release

AVAC, Access Bridge Call for Accelerated Ambition to Reach at Least Three Million People with Lenacapavir for HIV Prevention by the End of 2027 

New, more ambitious target will accelerate impact, drive affordability, and build momentum toward ending the HIV epidemic

NEW YORK and NAIROBI, October 21, 2026 – AVAC and Access Bridge today issued a global call to action urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. 

“Scientific breakthroughs only matter if they reach the people who need them,” said Mitchell Warren, Executive Director of AVAC. “LEN has the potential to transform HIV prevention and the overall epidemic response, but realizing that potential will require more urgency, more ambition, and more investment. Three million people reached by the end of 2027 is entirely feasible and an essential step toward ending new HIV infections. The field must commit to this: no less and no slower, with a push for more and faster.” 

Since results of efficacy trials were announced in 2024, injectable lenacapavir for PrEP (LEN) has generated enormous excitement. By the end of 2024, Gilead Sciences provided voluntary licenses to generic manufacturers and submitted multiple regulatory filings, and the Global Fund and PEPFAR initially committed to reach two million people over three years with LEN, and then increased it to three million in three years. As of October 2026, LEN is recommended by WHO; has 19 regulatory approvals, and counting; is being introduced in 36 implementation science projects; and is being introduced as part of public health programs in 29 countries, with support from the Global Fund and PEPFAR. 

“LEN represents one of the most promising advances in HIV prevention in decades. There is no time to waste. If we are to have any hope of ending AIDS as a public health threat by 2030, the global community must move beyond incremental implementation and seize the opportunity to rapidly scale access to a highly effective, long-acting prevention option, alongside treatment for all people living with HIV,” said Warren. 

Recent progress has demonstrated both the feasibility and demand for long-acting HIV prevention. Rapid regulatory approvals and national introduction efforts have laid the groundwork for broader access. At the same time, community demand for long-acting prevention options continues to grow, particularly among populations that face barriers to daily oral PrEP use. If stakeholders fumble the moment, demand risks outpacing supply by large margins, which will harm public trust in prevention efforts. 

The coming year represents a critical window for action. AVAC’s newly updated publication, Now What with Injectable LEN for PrEP: How to Translate Ambition into Accelerated Delivery and Impact outlines how to reach at least three million people with LEN by the end of 2027, including two potential scenarios for LEN market development, and where advocates can demand action. 

AVAC and Access Bridge have called for a LEN market development strategy that builds the market faster, secures lower product pricing, and achieves greater impact by 2030. The faster the market grows, the more transmission can be averted, more quickly the PrEP market can expand, and the greater the potential impact with LEN. This market development will also help build the programmatic infrastructure to expand choice and prepare for the possible introduction in 2028 of monthly oral alimatravir, if it is also shown to be safe and effective next year. 

“Three million people by the end of 2027 is a starting point, not an endpoint,” said Wawira Nyagah, Executive Director of Access Bridge. “We have a historic opportunity to reshape the trajectory of the HIV epidemic, and we are just getting started. The question is not whether the field can move quickly enough; it’s whether we choose to.” 

To reach at least three million people with LEN by the end of 2027 and 20 million by 2030, AVAC and Access Bridge are calling on:  

  1. Countries to provide ambitious forecasts based on actual demand and need and programmatic opportunity, not based on budget. 
 
  1. Global Fund and PEPFAR/GHSD to place orders now for enough doses for at least 2.4 million people in 2027 (given that 600,000 per years of LEN was ordered for 2026). In addition, advocacy needs to mobilize domestic resources and other new donors to increase volumes further. 
  1. National regulators to ensure rapid approval and/or regulatory waivers of generic LEN so that there are no delays in transitioning from Gilead to lower-priced generics, which should begin happening early next year, and that there is adequate and consistent access to product in-country. 
  1. Gilead and the approved generic manufacturers to commit the supplies to make this delivery schedule in 2027 and ensure commodity security.  
  1. Countries and communities to develop the programmatic infrastructure and robust demand creation to deliver that quantity as part of comprehensive prevention choice programs, so that product reaches people who need and want it and that no product is wasted. 

AVAC and Access Bridge emphasize that scaling LEN must be part of a broader commitment to prevention choice. The HIV prevention landscape is entering a new era: beyond LEN is the potential inclusion of new methods like the investigational monthly PrEP pill alimatravir (AMI), which is undergoing clinical trials now. The PrEP market from 2028 could be far more complex and competitive. 

No single product will meet everyone’s needs, but expanding access to a diverse range of prevention options is essential to ensuring that all individuals can find methods that work for them. AVAC and Access Bridge urge partners across sectors to align around a common objective now: turning the promise of LEN into measurable public health impact for millions of people around the world. 

Read the full Now What with Injectable LEN for PrEP: How to Translate Ambition into Accelerated Delivery and Impact here. 

No Time to Lose: Reaching At Least Three Million with LEN for PrEP by 2027

AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. This new, more ambitious target will drive affordability, build a sustainable PrEP market, and accelerate impact.

“Scientific breakthroughs only matter if they reach the people who need them. LEN has the potential to transform HIV prevention and the overall epidemic response, but realizing that potential will require more urgency, more ambition, and more investment. Three million people reached by the end of 2027 is entirely feasible and an essential step toward ending new HIV infections. The field must commit to this: no less and no slower, with a push for more and faster.”

Mitchell Warren
Executive Director, AVAC

Since results of efficacy trials were announced in 2024, injectable lenacapavir for PrEP (LEN) has generated enormous excitement. By the end of 2024, Gilead Sciences provided voluntary licenses to generic manufacturers and submitted multiple regulatory filings, and the Global Fund and PEPFAR initially committed to reach two million people over three years with LEN, and then increased it to three million in three years. As of October 2026, LEN is recommended by WHO; has 19 regulatory approvals, and counting; is being introduced in 36 implementation science projects; and is being introduced as part of public health programs in 29 countries, with support from the Global Fund and PEPFAR. 

Recent progress has demonstrated both the feasibility and demand for long-acting HIV prevention. Rapid regulatory approvals and national introduction efforts have laid the groundwork for broader access. At the same time, community demand for long-acting prevention options continues to grow, particularly among populations that face barriers to daily oral PrEP use. If stakeholders fumble the moment, demand risks outpacing supply by large margins, which will harm public trust in prevention efforts. 

The coming year represents a critical window for action. Our publication, Now What with Injectable LEN for PrEP: How to Translate Ambition into Accelerated Delivery and Impact outlines how to reach at least three million people with LEN by the end of 2027, including two potential scenarios for LEN market development, and where advocates can demand action. 

To reach at least three million people with LEN by the end of 2027 and 20 million by 2030, AVAC and Access Bridge are calling on:

  1. Countries to provide ambitious forecasts based on actual demand and need and programmatic opportunity, not based on budget.
  2. Global Fund and PEPFAR/GHSD to place orders now for enough doses for at least 2.4 million people in 2027 (given that 600,000 per years of LEN was ordered for 2026). In addition, advocacy needs to mobilize domestic resources and other new donors to increase volumes further.
  3. National regulators to ensure rapid approval and/or regulatory waivers of generic LEN so that there are no delays in transitioning from Gilead to lower-priced generics, which should begin happening early next year, and that there is adequate and consistent access to product in-country. 
  4. Gilead and the approved generic manufacturers to commit the supplies to make this delivery schedule in 2027 and ensure commodity security.
  5. Countries and communities to develop the programmatic infrastructure and robust demand creation to deliver that quantity as part of comprehensive prevention choice programs, so that product reaches people who need and want it and that no product is wasted.

“Three million people by the end of 2027 is a starting point, not an endpoint. We have a historic opportunity to reshape the trajectory of the HIV epidemic, and we are just getting started. The question is not whether the field can move quickly enough; it’s whether we choose to.”

Wawira Nyagah
Executive Director, Access Bridge

Scaling LEN must be part of a broader commitment to prevention choice. The HIV prevention landscape is entering a new era: beyond LEN is the potential inclusion of new methods like the investigational monthly PrEP pill alimatravir (AMI), which is undergoing clinical trials now. The PrEP market from 2028 could be far more complex and competitive. 

No single product will meet everyone’s needs, but expanding access to a diverse range of prevention options is essential to ensuring that all individuals can find methods that work for them. AVAC and Access Bridge urge partners across sectors to align around a common objective now: turning the promise of LEN into measurable public health impact for millions of people around the world. 

Read the full Now What with Injectable LEN for PrEP: How to Translate Ambition into Accelerated Delivery and Impact here. 

Avac Event

Save HIV Funding Rally

On Wednesday, October 21 join the Save HIV Funding campaign at IDWeek 2026 for a rally calling for the restoration and protection of federal HIV funding.

The #CutsKill Quilt art installation returns to IDWeek as a powerful visual reminder of the human impact of HIV funding cuts and the urgent need to protect HIV prevention, treatment, care and research.

Emceed by AVAC’s Mitchell Warren, the rally will feature Jeanne Marrazzo, IDSA, Anna Person, HIVMA, Ronald Johnson, U.S. People Living with HIV Caucus, Nada Fadul, HIVMA, Benjamin Brooks, Whitman-Walker Health and Jeremiah Johnson, PrEP4All / Save HIV Funding.

The event is open to all attending IDWeek.

Avac Event

Reaching Key Populations with Long-Acting PrEP: The launch of the PrEP Power Demand Generation Toolkit

The need for PrEP amongst key populations (KPs) is high yet KPs remain underserved in many PrEP programs. To help address this need, Global Black Gay Men Connect, Access Bridge, and AVAC, alongside local partners in Eswatini, Kenya, and Zambia, convened Human Centered Design (HCD) Lite workshops to gather insights to develop KP-focused messaging on long-acting PrEP.  The resulting findings were synthesized into a demand generation toolkit, consisting of summary insights, guidance for developing materials, and sample materials. The toolkit forms a valuable resource for KP-focused organizations and HIV prevention implementers to adapt to their contexts and support their efforts to engage KP communities on long-acting PrEP.

Access the toolkit at prepwatch.org/preppowertoolkit.

In this webinar, we discussed the following:

  • The HCD Lite process, and how we rapidly gathered and translated insights into demand generation materials
  • Key insights on how to reach KPs with long-acting PrEP 
  • How to use and adapt the toolkit for your local context 

From Research to Access: The Community Statement from the Global Community Advisory Group (GCAG) on the Future of Alima (Alimatravir) for HIV Prevention

The EXPrESSIVE-10 Global Community Advisory Group (GCAG) released a statement on the future of alimatravir and HIV prevention. The statement reflects community perspectives and priorities around prevention choice, meaningful community engagement, equitable access, and ensuring that communities have a voice as research progresses toward potential introduction. As the GCAG writes, “The test is now whether early planning can translate into faster, more equitable action. An access plan is valuable not because it is announced, but because it creates a pathway that can be tracked, challenged, and delivered.”